The global Guillain-Barre Syndrome (GBS) Market, valued at US$ 591.3 million in 2022, is projected to grow at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2031, reaching US$ 890.2 million by 2031. GBS is a rare autoimmune neurological disorder where the immune system attacks peripheral nerves, causing muscle weakness and, in severe cases, paralysis. The market, encompassing...